Progyny (NASDAQ:PGNY) Issues Q2 2026 Earnings Guidance

Progyny (NASDAQ:PGNY) updated its second quarter 2026 earnings guidance on Thursday. The company provided EPS guidance of 0.500-0.53 for the period, compared to the consensus EPS estimate of 0.440. The company issued revenue guidance of $342.0 million-$355.0 million, compared to the consensus revenue estimate of $349.5 million. Progyny also updated its FY 2026 guidance to 1.980-2.09 EPS.

Wall Street Analysts Forecast Growth

PGNY has been the topic of several research analyst reports. Zacks Research cut shares of Progyny from a “strong-buy” rating to a “hold” rating in a research report on Friday, January 30th. Canaccord Genuity Group decreased their target price on shares of Progyny from $26.00 to $19.00 and set a “hold” rating on the stock in a research report on Wednesday, March 11th. KeyCorp decreased their target price on shares of Progyny from $32.00 to $28.00 and set an “overweight” rating on the stock in a research report on Monday, March 2nd. Barclays decreased their target price on shares of Progyny from $29.00 to $23.00 and set an “overweight” rating on the stock in a research report on Friday, March 20th. Finally, JPMorgan Chase & Co. set a $35.00 target price on shares of Progyny in a research report on Wednesday, January 21st. Nine analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat, Progyny presently has a consensus rating of “Moderate Buy” and a consensus target price of $27.91.

Progyny Price Performance

NASDAQ PGNY traded up $4.04 during mid-day trading on Friday, hitting $23.20. The company’s stock had a trading volume of 2,608,719 shares, compared to its average volume of 1,511,258. Progyny has a 52-week low of $16.10 and a 52-week high of $28.75. The stock’s fifty day simple moving average is $17.87 and its two-hundred day simple moving average is $21.69. The firm has a market capitalization of $1.82 billion, a P/E ratio of 35.55, a price-to-earnings-growth ratio of 1.08 and a beta of 0.91.

Progyny (NASDAQ:PGNY) last issued its quarterly earnings data on Thursday, May 7th. The company reported $0.50 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.44 by $0.06. The company had revenue of $328.50 million during the quarter, compared to the consensus estimate of $326.47 million. Progyny had a net margin of 4.54% and a return on equity of 11.37%. Progyny’s revenue for the quarter was down 26.4% on a year-over-year basis. During the same quarter last year, the company earned $0.17 earnings per share. Progyny has set its FY 2026 guidance at 1.980-2.09 EPS and its Q2 2026 guidance at 0.500-0.53 EPS. On average, equities analysts forecast that Progyny will post 1.12 earnings per share for the current fiscal year.

Insider Activity

In other news, EVP Allison Swartz sold 4,657 shares of the firm’s stock in a transaction that occurred on Tuesday, March 3rd. The shares were sold at an average price of $17.40, for a total transaction of $81,031.80. Following the completion of the sale, the executive vice president owned 89,879 shares of the company’s stock, valued at approximately $1,563,894.60. This trade represents a 4.93% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders have sold a total of 7,455 shares of company stock worth $129,515 in the last 90 days. Company insiders own 9.90% of the company’s stock.

Progyny News Roundup

Here are the key news stories impacting Progyny this week:

• Positive Sentiment: Q1 beat on EPS and revenue: Progyny reported $0.50 EPS vs. $0.44 consensus and $328.5M revenue vs. ~$326.5M expected — an earnings surprise that helped lift the stock. Progyny (PGNY) Q1 Earnings and Revenues Beat Estimates
• Positive Sentiment: Upgraded profit outlook: Management set FY2026 EPS guidance at $1.98–$2.09 and Q2 EPS at $0.50–$0.53, both above consensus — supports better-than-expected profitability trajectory. Progyny, Inc. Announces First Quarter 2026 Results
• Positive Sentiment: Capital return and demand signals: Company reported higher member engagement in the selling season and has repurchased ~8.8M shares since November, which can boost EPS and signal management confidence. Progyny, Inc. Announces First Quarter 2026 Results
• Neutral Sentiment: Conference call commentary: Management emphasized member engagement and demand for women’s health services; see the full Q1 call transcript for detail that may affect investor models. Progyny, Inc. (PGNY) Q1 2026 Earnings Call Transcript
• Negative Sentiment: Revenue still down materially: Q1 revenue fell ~26% year-over-year, a clear reminder that top-line recovery is incomplete and could limit multiple expansion until growth stabilizes. Progyny: Q1 Earnings Snapshot
• Negative Sentiment: Investor concern over revenue guidance and growth durability: Some analysts warn that “flat” or cautious revenue assumptions could change the bull case if demand momentum slows, which adds volatility risk despite the EPS beat. The Bull Case For Progyny (PGNY) Could Change Following Flat Q1 2026 Revenue Guidance Concerns

Institutional Trading of Progyny

A number of hedge funds have recently made changes to their positions in the stock. State Street Corp increased its stake in Progyny by 1.5% during the fourth quarter. State Street Corp now owns 2,953,186 shares of the company’s stock valued at $75,838,000 after purchasing an additional 44,642 shares during the last quarter. Wellington Management Group LLP increased its stake in Progyny by 260.9% during the fourth quarter. Wellington Management Group LLP now owns 2,243,268 shares of the company’s stock valued at $57,607,000 after purchasing an additional 1,621,688 shares during the last quarter. Ameriprise Financial Inc. increased its stake in Progyny by 37.6% during the second quarter. Ameriprise Financial Inc. now owns 1,996,957 shares of the company’s stock valued at $43,933,000 after purchasing an additional 545,431 shares during the last quarter. Geode Capital Management LLC increased its stake in Progyny by 1.1% during the fourth quarter. Geode Capital Management LLC now owns 1,972,219 shares of the company’s stock valued at $50,655,000 after purchasing an additional 20,533 shares during the last quarter. Finally, Dimensional Fund Advisors LP increased its stake in Progyny by 12.1% during the fourth quarter. Dimensional Fund Advisors LP now owns 1,712,039 shares of the company’s stock valued at $43,966,000 after purchasing an additional 184,679 shares during the last quarter. Institutional investors and hedge funds own 94.93% of the company’s stock.

About Progyny

Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company’s digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.

The core of Progyny’s offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.